Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Treatment of mesothelioma with gene-modified PA1STK cells and ganciclovir: a phase I study

Abstract

Mesothelioma is an incurable cancer of the pleura with a life expectancy of less than 1 year. On the basis of in vivo efficacy seen with the herpes simplex virus type 1 thymidine kinase (HSVtk) suicide gene-modified PA1STK cell line and ganciclovir (GCV) in a murine model of mesothelioma, a first in humans, clinical trial was designed for this therapeutic concept. The study was a phase I clinical trial using direct infusion of escalating doses of HSVtk suicide gene-modified PA1STK cells directly into tumor-associated pleural effusions followed by 7 days of intravenous GCV infusion. Therapeutic levels of GCV in both serum and pleura were achieved within 1 h, and GCV trough levels remained above the therapeutic threshold for the duration of GCV treatment. The treatment was well tolerated without any Grade 3 or 4 toxicity observed. Significant inductions of both Th1 and Th2 cytokines up to 20-fold over baseline were observed. No significant differences were seen between serum and pleura cytokine profiles, with the exception of interleukin-10, which was consistently elevated in the pleura specimens. No objective radiographic responses were observed. The data indicate significant immunological responses and validate the principal anti-tumor mechanisms observed in preclinical models of mesothelioma in a human clinical trial.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411–422.

    Article  CAS  PubMed  Google Scholar 

  2. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–723.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Moolten FL . Drug sensitivity suicide genes for selective cancer chemotherapy. Cancer Gene Ther 1994; 1: 279–287.

    CAS  PubMed  Google Scholar 

  4. Ashton WT, Karkas JD, Field AK, Tolman RL . Activation by thymidine kinase and potent antiherpetic activity of 2′-nor-2′-deoxyguanosine (2′NDG). Biochem Biophys Res Commun 1982; 108: 1716–1721.

    Article  CAS  PubMed  Google Scholar 

  5. Tiberghien P . Use of suicide genes in gene therapy. J Leukoc Biol 1994; 56: 203–209.

    Article  CAS  PubMed  Google Scholar 

  6. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL et al. The ‘bystander effect’: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274–5283.

    CAS  PubMed  Google Scholar 

  7. Ramesh R, Marrogi AJ, Munshi A, Abboud CN, Freeman SM . In vivo analysis of the ‘bystander effect’: a cytokine cascade. Exp Hematol 1996; 24: 829–838.

    CAS  PubMed  Google Scholar 

  8. Freeman SM, Whartenby KA, Freeman JL, Abboud CN, Marrogi AJ . In situ use of suicide genes for cancer therapy. Semin Oncol 1996; 23: 31–45.

    CAS  PubMed  Google Scholar 

  9. Schwarzenberger P, Lei D, Freeman SM, Ye P, Weinacker A, Theodossiou C et al. Antitumor activity with the HSV-tk-gene-modified cell line PA-1-STK in malignant mesothelioma. Am J Respir Cell Mol Biol 1998; 19: 333–337.

    Article  CAS  PubMed  Google Scholar 

  10. Ramesh R, Munshi A, Marrogi AJ, Freeman SM . Enhancement of tumor killing using a combination of tumor immunization and HSV-tk suicide gene therapy. Int J Cancer 1999; 80: 380–386.

    Article  CAS  PubMed  Google Scholar 

  11. Ramesh R, Munshi A, Abboud CN, Marrogi AJ, Freeman SM . Expression of costimulatory molecules: B7 and ICAM up-regulation after treatment with a suicide gene. Cancer Gene Ther 1996; 3: 373–384.

    CAS  PubMed  Google Scholar 

  12. Whartenby KA, Abboud CN, Marrogi AJ, Ramesh R, Freeman SM . The biology of cancer gene therapy. Lab Invest 1995; 72: 131–145.

    CAS  PubMed  Google Scholar 

  13. Freeman SM, Ramesh R, Marrogi AJ . Immune system in suicide-gene therapy. Lancet 1997; 349: 2–3.

    Article  CAS  PubMed  Google Scholar 

  14. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636–2644.

    Article  CAS  PubMed  Google Scholar 

  15. Lucchi M, Chella A, Melfi F, Dini P, Ambrogi M, Fino L et al. A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma. Eur J Cardiothorac Surg 2007; 31: 529–533; discussion 533-534.

    Article  PubMed  Google Scholar 

  16. Astoul P, Picat-Joossen D, Viallat JR, Boutin C . Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study. Cancer 1998; 83: 2099–2104.

    Article  CAS  PubMed  Google Scholar 

  17. Schwarzenberger P, Byrne P, Kolls JK . Immunotherapy-based treatment strategies for malignant mesothelioma. Curr Opin Mol Ther 1999; 1: 104–111.

    CAS  PubMed  Google Scholar 

  18. Treat J, Kaiser LR, Sterman DH, Litzky L, Davis A, Wilson JM et al. Treatment of advanced mesothelioma with the recombinant adenovirus H5.010RSVTK: a phase 1 trial (BB-IND 6274). Hum Gene Ther 1996; 7: 2047–2057.

    Article  CAS  PubMed  Google Scholar 

  19. Sterman DH, Kaiser LR, Albelda SM . Gene therapy for malignant pleural mesothelioma. Hematol Oncol Clin North Am 1998; 12: 553–568.

    Article  CAS  PubMed  Google Scholar 

  20. Schwarzenberger P, Harrison L, Weinacker A, Marrogi A, Byrne P, Ramesh R et al. The treatment of malignant mesothelioma with a gene modified cancer cell line: a phase I study. Hum Gene Ther 1998; 9: 2641–2649.

    CAS  PubMed  Google Scholar 

  21. Moolten FL . Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276–5281.

    CAS  PubMed  Google Scholar 

  22. Moolten FL, Wells JM . Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 1990; 82: 297–300.

    Article  CAS  PubMed  Google Scholar 

  23. Ljungman P . Cytomegalovirus pneumonia: presentation, diagnosis, and treatment. Semin Respir Infect 1995; 10: 209–215.

    CAS  PubMed  Google Scholar 

  24. Harrison LH, Schwarzenberger PO, Byrne PS, Marrogi AJ, Kolls JK, McCarthy KE . Gene-modified PA1-STK cells home to tumor sites in patients with malignant pleural mesothelioma. Ann Thorac Surg 2000; 70: 407–411.

    Article  PubMed  Google Scholar 

  25. Sterman DH, Recio A, Haas AR, Vachani A, Katz SI, Gillespie CT et al. A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Mol Ther 2010; 18: 852–860.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Vachani A, Moon E, Wakeam E, Albelda SM . Gene therapy for mesothelioma and lung cancer. Am J Respir Cell Mol Biol 2010; 42: 385–393.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Dr Scott Freeman for providing the PA1STK cell line. The study was supported in part by the Tulane/LSU General Clinical Research grant 5M01RR005096.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to P Schwarzenberger.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schwarzenberger, P., Byrne, P., Gaumer, R. et al. Treatment of mesothelioma with gene-modified PA1STK cells and ganciclovir: a phase I study. Cancer Gene Ther 18, 906–912 (2011). https://doi.org/10.1038/cgt.2011.60

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cgt.2011.60

Keywords

This article is cited by

Search

Quick links